UroDev Medical, formerly known as Spinal Singularity, this week announced it appointed Matt Monarski as CEO and that it would be moving its headquarters to Minneapolis.
Monarski joins the company with nearly 30 years of global commercial experience focused on advancing new urology, gynecology and orthopedic medical devices. Prior to joining the company, Monarski held numerous leadership roles at NeoTract and Teleflex, where he was responsible for driving the adoption of the company’s UroLift System. He has also held numerous marketing and sales roles at American Medical Systems and Tornier.
“UroDev Medical is poised to successfully address a condition that affects millions of men in the U.S., and I couldn’t be more excited to join this team during this critical time in the company’s evolution,” said Monarski. “I believe in the potential of this disruptive technology to fill a growing clinical need in the urology space, and I look forward to leading the company through its next phase to submit for FDA clearance and prepare for commercialization.”
The recent rebranding of the company’s name reflects its mission to improve the lives of people with permanent indwelling urinary catheters or live with intermittent catheterizations due to urinary retention. The company also said it is looking to move beyond spinal injury patient through changing its name.
Within the rebranding, UroDev Medical also announced that it is relocated its headquarters from San Clemente, Calif. to Minneapolis.
“We have evolved significantly as a company and wanted to have a name that reflects this growth,” chief technology officer Derek Herrera said in a news release. “We believe the IntelliFlow System will not only help men suffering from urinary retention due to spinal injury, but all men experiencing the disruptive symptoms of this condition. I’m excited with the progress we’ve made as we approach our goal of bringing the product to the U.S. market. This is the perfect time to welcome Matt, a proven leader in bringing innovative solutions to the field of urology, as we prepare to become a commercial-stage company.”
